

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Locally advanced or metastatic urothelial carcinoma

AND ALL of the following:

- a. Susceptible FGFR3 genetic alterations
- b. Disease progression on or after at least one line of prior systemic therapy
- c. Prescriber agrees to monitor phosphate levels monthly for hyperphosphatemia
- d. Prescriber agrees to monitor for ocular disorders
- e. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Balversa and for one month after the last dose
- f. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Balversa and for one month after the last dose

Prior - Approval Limits

Duration 6 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Locally advanced or metastatic urothelial carcinoma

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity

- b. Prescriber agrees to monitor phosphate levels monthly for hyperphosphatemia
- c. Prescriber agrees to monitor for ocular disorders
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Balversa and for one month after the last dose
- e. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Balversa and for one month after the last dose

Prior - Approval *Renewal* Limits

Duration 12 months